ECSP24008791A - Composiciones farmacéuticas de un anticuerpo contra pd-1 y uso de las mismas - Google Patents

Composiciones farmacéuticas de un anticuerpo contra pd-1 y uso de las mismas

Info

Publication number
ECSP24008791A
ECSP24008791A ECSENADI20248791A ECDI202408791A ECSP24008791A EC SP24008791 A ECSP24008791 A EC SP24008791A EC SENADI20248791 A ECSENADI20248791 A EC SENADI20248791A EC DI202408791 A ECDI202408791 A EC DI202408791A EC SP24008791 A ECSP24008791 A EC SP24008791A
Authority
EC
Ecuador
Prior art keywords
pharmaceutical compositions
antibody against
retifanlimab
cancer
treatment
Prior art date
Application number
ECSENADI20248791A
Other languages
English (en)
Spanish (es)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of ECSP24008791A publication Critical patent/ECSP24008791A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
ECSENADI20248791A 2021-07-09 2024-02-02 Composiciones farmacéuticas de un anticuerpo contra pd-1 y uso de las mismas ECSP24008791A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163220006P 2021-07-09 2021-07-09

Publications (1)

Publication Number Publication Date
ECSP24008791A true ECSP24008791A (es) 2024-03-01

Family

ID=82608118

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI20248791A ECSP24008791A (es) 2021-07-09 2024-02-02 Composiciones farmacéuticas de un anticuerpo contra pd-1 y uso de las mismas

Country Status (17)

Country Link
US (2) US12364756B2 (https=)
EP (1) EP4366692A1 (https=)
JP (1) JP2024525566A (https=)
KR (1) KR20240035533A (https=)
CN (1) CN118215465A (https=)
AR (1) AR126404A1 (https=)
AU (1) AU2022307332A1 (https=)
CA (1) CA3224640A1 (https=)
CL (1) CL2024000077A1 (https=)
CO (1) CO2024000198A2 (https=)
CR (1) CR20240065A (https=)
EC (1) ECSP24008791A (https=)
IL (1) IL309985A (https=)
MX (1) MX2024000268A (https=)
PE (1) PE20240797A1 (https=)
TW (1) TW202308694A (https=)
WO (1) WO2023283049A1 (https=)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1478394T1 (sl) * 2002-02-27 2008-12-31 Immunex Corp STABILIZIRAN TNFR-Fc SESTAVEK Z ARGININOM
HUE068868T2 (hu) * 2015-07-30 2025-02-28 Macrogenics Inc PD-1-hez kötõdõ molekulák és alkalmazásukra szolgáló eljárások
JOP20190260A1 (ar) * 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
CN114632150B (zh) * 2017-11-02 2023-12-19 正大天晴药业集团股份有限公司 一种抗pd-l1人源化单克隆抗体的药物组合物
IL277095B2 (en) * 2018-03-07 2025-10-01 Pfizer Preparations containing anti-PD-1 antibody
CN110404066B (zh) * 2018-04-28 2022-06-17 齐鲁制药有限公司 一种抗人pd-1的单克隆抗体制剂、联合用药物及其用途
KR20220044527A (ko) 2019-08-01 2022-04-08 인사이트 코포레이션 Ido 억제제의 투여 요법
KR20220041099A (ko) 2019-08-05 2022-03-31 오노 야꾸힝 고교 가부시키가이샤 면역 체크포인트 저해약의 유효성 판정 바이오마커

Also Published As

Publication number Publication date
AR126404A1 (es) 2023-10-11
PE20240797A1 (es) 2024-04-18
CL2024000077A1 (es) 2024-08-23
MX2024000268A (es) 2024-01-31
US20230025464A1 (en) 2023-01-26
WO2023283049A1 (en) 2023-01-12
IL309985A (en) 2024-03-01
CR20240065A (es) 2024-04-08
KR20240035533A (ko) 2024-03-15
CN118215465A (zh) 2024-06-18
CO2024000198A2 (es) 2024-02-05
TW202308694A (zh) 2023-03-01
EP4366692A1 (en) 2024-05-15
AU2022307332A1 (en) 2024-01-18
US12364756B2 (en) 2025-07-22
CA3224640A1 (en) 2023-01-12
JP2024525566A (ja) 2024-07-12
US20250345422A1 (en) 2025-11-13

Similar Documents

Publication Publication Date Title
JOP20220163B1 (ar) مركب بيريدازينيل-ثيازول كربوكساميد
BR112023015715A2 (pt) Inibidor de cdk
CL2019003032A1 (es) Formulaciones de anticuerpos humanos anti-rankl y métodos de uso de estas.
ECSP19078502A (es) Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso
EA201792273A1 (ru) Композиции, содержащие комбинацию анти-pd-1 антитела и другого антитела
MX2019002564A (es) Composiciones de agente de unión de albúmina-paclitaxel y métodos de uso y elaboración de las mismas.
BR112020009655A8 (pt) Anticorpo, usos de um anticorpo e uso de uma combinação farmacêutica
MX2021000299A (es) Preparados combinados para el tratamiento contra el cancer o infecciones.
BRPI0407375A (pt) Métodos para tratar dor por meio da administração de um antagonista do fator de crescimento neural e u nsaid e composições contendo os mesmos
CL2019002671A1 (es) Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1.
MX2020008445A (es) Metodos para tratar el cancer con anticuerpos anti-pd-1.
BR112022008558A2 (pt) Método de tratamento para câncer, tratamento de combinação de nivolumabe e anticorpos anti-pvrig, e, uso
MX2022009936A (es) Anticuerpos que se unen al dominio v-set que contiene el inhibidor de activacion de celulas t 1 (b7h4).
BR112023012432A2 (pt) Composições e métodos para modificação genética de ciita em uma célula
BR112021012056A2 (pt) Inibidor da expressão gênica do hbv, agente que reduz a carga antigênica de hbv, composições para uso no tratamento de uma infecção crônica por hbv, usos de um inibidor da expressão gênica do hbv e de um agente que reduz a carga antigênica de hbv, métodos de tratamento da infecção crônica por hbv e kit
MX2023001963A (es) Composiciones farmaceuticas hipertonicas que contienen un agente quimioprotector antiplatino.
CL2024002767A1 (es) Moduladores de nlrp3
ECSP21060917A (es) Formulación de anticuerpos terapéuticos
ECSP22043592A (es) Inhibidores de egfr alost?ricos y m?todos de uso de los mismos
MX2021008022A (es) Proteínas heterodiméricas para modular células t gamma delta.
CL2025002366A1 (es) Compuesto que contiene trifluorometilsulfonilo.
Wang et al. Enhancement of arabinocytosine (AraC) toxicity to AML cells by a differentiation agent combination
MX2021013888A (es) Composiciones que comprenden efedrina o una sal de efedrina y metodos de fabricacion y uso de las mismas.
MX2021003263A (es) Combinacion de un antagonista de proteina de muerte programada 1 (pd-1), un inhibidor de ataxia telangiectasia y proteina relacionada con rad3 (atr) y un agente de platino para el tratamiento de cancer.
ECSP24008791A (es) Composiciones farmacéuticas de un anticuerpo contra pd-1 y uso de las mismas